Form 8-K - Current report:
SEC Accession No. 0001193125-24-230283
Filing Date
2024-10-01
Accepted
2024-10-01 16:59:02
Documents
19
Period of Report
2024-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d895981d8k.htm   iXBRL 8-K 41884
2 EX-4.1 d895981dex41.htm EX-4.1 81991
3 EX-4.2 d895981dex42.htm EX-4.2 84378
4 EX-4.3 d895981dex43.htm EX-4.3 8189
5 EX-10.1 d895981dex101.htm EX-10.1 308032
6 EX-10.2 d895981dex102.htm EX-10.2 75228
10 GRAPHIC g895981dsp96.jpg GRAPHIC 27753
  Complete submission text file 0001193125-24-230283.txt   914871

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA inab-20240930.xsd EX-101.SCH 2836
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20240930_lab.xml EX-101.LAB 18738
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20240930_pre.xml EX-101.PRE 11698
21 EXTRACTED XBRL INSTANCE DOCUMENT d895981d8k_htm.xml XML 3742
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 241344127
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)